
EDIT
Healthcare · Biotechnology · $334.9M market cap
$2.17+0.03 (+1.4%)Nov 13, 4:09 PM EST
Next report
Before the open
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +24.1% over 90 days · 30-day revisions 6 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 8, 2027 · upcoming | Before the open | -0.21 | — | — |
| Nov 9, 2026 | Before the open | -0.21 | -0.15 | +28.6% |
| Aug 5, 2026 | After the close | -0.30 | -0.15 | +50.0% |
| May 5, 2026 | Before the open | -0.24 | -0.26 | -8.3% |
| Feb 19, 2026 | Time not confirmed | -0.23 | -0.06 | +73.9% |
| Nov 10, 2025 | Before the open | -0.38 | -0.28 | +26.3% |
| Aug 12, 2025 | After the close | -0.38 | -0.32 | +15.8% |
| May 12, 2025 | After the close | -0.59 | -0.92 | -55.9% |
| Feb 26, 2025 | Before the open | -0.33 | -0.55 | -67.4% |
| Nov 4, 2024 | Before the open | -0.77 | -0.75 | +2.6% |
| Aug 7, 2024 | Before the open | -0.71 | -0.82 | -15.5% |
| May 8, 2024 | Before the open | -0.64 | -0.76 | -18.8% |
| Feb 28, 2024 | Before the open | -0.54 |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also…
| -0.23 |
| +57.4% |
| Nov 3, 2023 | Before the open | -0.58 | -0.55 | +5.2% |
| Aug 2, 2023 | Before the open | -0.77 | -0.56 | +27.3% |
| May 5, 2023 | Before the open | -0.78 | -0.71 | +9.0% |
| Feb 22, 2023 | Before the open | -0.81 | -0.88 | -8.6% |
| Nov 2, 2022 | Before the open | -0.85 | -0.81 | +4.7% |
| Aug 3, 2022 | Before the open | -0.80 | -0.78 | +2.5% |
| May 4, 2022 | Before the open | -0.79 | -0.74 | +6.3% |
| Feb 24, 2022 | Before the open | -0.72 | -0.61 | +15.3% |
| Nov 8, 2021 | Before the open | -0.81 | -0.57 | +29.6% |
| Aug 4, 2021 | Before the open | -0.81 | -0.81 | 0.0% |
| May 5, 2021 | Before the open | -0.71 | -0.86 | -21.1% |
| Feb 25, 2021 | Before the open | -0.74 | -1.00 | -35.1% |
| Nov 5, 2020 | After the close | -0.63 | 0.12 | +119.0% |
| Aug 6, 2020 | After the close | -0.82 | -0.43 | +47.6% |
| May 7, 2020 | Before the open | -0.79 | -0.69 | +12.7% |
| Feb 26, 2020 | After the close | 0.06 | -0.74 | -1333.3% |
| Nov 12, 2019 | After the close | -0.73 | -0.66 | +9.6% |
| Aug 6, 2019 | After the close | -0.62 | -0.69 | -11.3% |
| May 7, 2019 | After the close | -0.64 | -0.60 | +6.3% |
| Feb 28, 2019 | After the close | -0.32 | -0.52 | -62.5% |
| Nov 7, 2018 | After the close | -0.81 | -0.32 | +60.5% |
| Aug 6, 2018 | After the close | -0.66 | -0.82 | -24.2% |
| May 3, 2018 | After the close | -0.80 | -0.67 | +16.3% |
| Mar 6, 2018 | After the close | -0.78 | -0.84 | -7.7% |